{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:27:38Z","timestamp":1793924858916,"version":"4.8.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:00:00Z","timestamp":1792886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.vaccine.2026.129268","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:49:10Z","timestamp":1792597750000},"page":"129268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Phase 2 trial to evaluate the safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine (IVT-PCV25) in infants"],"prefix":"10.1016","volume":"94","author":[{"given":"Lulu","family":"Bravo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Bermal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edison","family":"Alberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"January Anne","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angela","family":"Maronilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Christine Joy","family":"Tanteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue Ann","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W.","family":"Rockhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indah","family":"Andi-Lolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan J.","family":"Vilms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybil A.","family":"Tasker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf L.","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash","family":"Kapre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Borkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129268_bb0005","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1473-3099(25)00689-9","article-title":"Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the global burden of disease study 2023","volume":"26","author":"Infections GBDLR, Antimicrobial Resistance C","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.129268_bb0010","author":"WHO"},{"key":"10.1016\/j.vaccine.2026.129268_bb0015","first-page":"1","article-title":"Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"49","author":"Advisory Committee on Immunization","year":"2000","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.vaccine.2026.129268_bb0020","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0264-410X(99)00238-8","article-title":"Studies on a Hib-tetanus toxoid conjugate vaccine: effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine","volume":"18","author":"Carlsson","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129268_bb0025","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1586\/erv.11.14","article-title":"Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy","volume":"10","author":"Blanchard-Rohner","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.vaccine.2026.129268_bb0030","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1473-3099(24)00588-7","article-title":"Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis","volume":"25","author":"Garcia Quesada","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.129268_bb0035","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-0377","article-title":"Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease","volume":"145","author":"Berman-Rosa","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.129268_bb0040","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(23)00706-5","article-title":"Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study","volume":"24","author":"Bertran","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.129268_bb0045","author":"UK Health Security Agency"},{"key":"10.1016\/j.vaccine.2026.129268_bb0050","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the global burden of disease study 2019","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.129268_bb0055","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1080\/21645515.2021.1985353","article-title":"Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines","volume":"17","author":"Du","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.vaccine.2026.129268_bb0060","doi-asserted-by":"crossref","first-page":"18977","DOI":"10.1038\/s41598-020-75691-5","article-title":"Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency","volume":"10","author":"Lochen","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vaccine.2026.129268_bb0065","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-060428","article-title":"Safety and tolerability of V114 pneumococcal vaccine in infants: a phase 3 study","volume":"152","author":"Banniettis","year":"2023","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.129268_bb0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/14760584.2023.2294153","article-title":"PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children","volume":"23","author":"Chapman","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.vaccine.2026.129268_bb0075","article-title":"PCV20 in pediatric pneumococcal prevention: expanded coverage, remaining challenges","volume":"16","author":"Principi","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2026.129268_bb0080","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2026.2616144","article-title":"An overview of the clinical development of the 20-valent pneumococcal conjugate vaccine in adults","volume":"22","author":"McElwee","year":"2026","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.vaccine.2026.129268_bb0085","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/INF.0000000000004334","article-title":"A phase three study of the safety and immunogenicity of a four-dose series of 20-valent pneumococcal conjugate vaccine in healthy infants","volume":"43","author":"Senders","year":"2024","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.vaccine.2026.129268_bb0090","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: a review","volume":"28","author":"Dagan","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129268_bb0095","doi-asserted-by":"crossref","first-page":"ofae220","DOI":"10.1093\/ofid\/ofae220","article-title":"Immunogenicity of current and next-generation pneumococcal conjugate vaccines in children: current challenges and upcoming opportunities","volume":"11","author":"Feemster","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.129268_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2026.128236","article-title":"Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: results from 2 randomised, controlled clinical trials","volume":"75","author":"Langley","year":"2026","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129268_bb0105","article-title":"Pneumococcal conjugate vaccine implementation in middle-income countries","volume":"9","author":"Tricarico","year":"2017","journal-title":"Pneumonia (Nathan)"},{"key":"10.1016\/j.vaccine.2026.129268_bb0110","first-page":"151","article-title":"A narrative review of pneumococcal conjugate vaccine choices for greater access and protection against pneumococcal diseases in the Philippines","volume":"59","author":"Lota","year":"2025","journal-title":"Acta Med Philipp"},{"key":"10.1016\/j.vaccine.2026.129268_bb0115","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.vaccine.2019.10.064","article-title":"Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: a phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14\u202fweeks and 9\u202fmonths of age","volume":"38","author":"Bravo","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129268_bb0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijid.2016.02.015","article-title":"Comparison of the immunogenicity and safety of pentavalent vaccine Quinvaxem in a compact prefilled auto-disabled (cPAD) injection system versus single-dose vials in healthy infants: a phase 3, open-label, randomized, parallel-group, non-inferiority study","volume":"46","author":"Capeding","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.129268_bb0125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/INF.0b013e3181f2da06","article-title":"Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV\/Hib and poliovirus vaccines","volume":"30","author":"Bermal","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.vaccine.2026.129268_bb0130","article-title":"Immunogenicity and safety of a quadrivalent influenza vaccine in population aged 3 years and older in Chile and the Philippines: a phase 3, non-inferiority, double-blind, randomized controlled clinical trial","volume":"12","author":"Yang","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.129268_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103349","article-title":"Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, phase 3 trial","volume":"86","author":"Rumyantsev","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2026.129268_bb0140","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.129268_bb0145","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41541-022-00538-1","article-title":"Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data","volume":"7","author":"Ryman","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.129268_bb0150","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1016\/j.vaccine.2007.01.119","article-title":"Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies","volume":"25","author":"Siber","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129268_bb0155","author":"FDA"},{"key":"10.1016\/j.vaccine.2026.129268_bb0160","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1128\/CVI.00415-08","article-title":"Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum","volume":"16","author":"Marchese","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.vaccine.2026.129268_bb0165","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.4155\/bio-2020-0023","article-title":"Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA","volume":"12","author":"Nolan","year":"2020","journal-title":"Bioanalysis"},{"key":"10.1016\/j.vaccine.2026.129268_bb0170","author":"WHO"},{"key":"10.1016\/j.vaccine.2026.129268_bb0175","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/CVI.00086-12","article-title":"Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20","volume":"19","author":"Burton","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.vaccine.2026.129268_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.128186","article-title":"Determining the dose-response relationship for pneumococcal conjugate vaccines: a nested analysis of the fractional dose PCV trial","volume":"73","author":"Martinez-de-Albeniz","year":"2026","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129268_bb0185","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1128\/CVI.00248-12","article-title":"Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine","volume":"19","author":"Simell","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.vaccine.2026.129268_bb0190","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1016\/j.vaccine.2013.09.073","article-title":"Levels and functionality of antibodies after pneumococcal conjugate vaccine in schedules with different timing of the booster dose","volume":"31","author":"van Westen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129268_bb0195","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41541-025-01152-7","article-title":"Age-related decline in IgM responses associate with reduced opsonophagocytic activity following PCV13 vaccination","volume":"10","author":"Visser","year":"2025","journal-title":"NPJ Vaccines."},{"key":"10.1016\/j.vaccine.2026.129268_bb0200","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1128\/CVI.05313-11","article-title":"Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption","volume":"18","author":"Schuerman","year":"2011","journal-title":"Clin. Vaccine Immunol."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26010777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26010777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:54:30Z","timestamp":1793922870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26010777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":40,"alternative-id":["S0264410X26010777"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129268","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 trial to evaluate the safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine (IVT-PCV25) in infants","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129268"}}